WAUKEGAN, Ill.--(BUSINESS WIRE)--NEOPHARM, Inc. (NASDAQ: NEOL), today announced its first quarter 2007 financial results. For the first quarter ended March 31, 2007, NEOPHARM reported a net loss of $5.5 million, or $0.19 per diluted share, as compared to $7.7 million, or $0.28 per share, for the same period last year, which represents a $2.2 million, or 29%, reduction. This reduction was driven primarily by a $1.0 million decrease in project costs related to CINTREDEKIN BESUDOTOX and decreased personnel costs in the first quarter of 2007 compared to 2006 as a result of the restructuring initiatives completed during 2006.
